Plasminogen Activator Inhibitor-1 Activity in Type 2 Diabetes | Zendy

Laima Brazionis | Zendy; Kevin Rowley | Zendy; Alicia J. Jenkins | Zendy; Catherine Itsiopoulos | Zendy; Kerin O’Dea | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Plasminogen Activator Inhibitor-1 Activity in Type 2 Diabetes

Author(s) -

Laima Brazionis,

Kevin Rowley,

Alicia J. Jenkins,

Catherine Itsiopoulos,

Kerin O’Dea

Publication year - 2008

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.107.160168

Subject(s) - medicine , retinopathy , plasminogen activator , diabetes mellitus , plasminogen activator inhibitor 1 , type 2 diabetes , diabetic retinopathy , fibrinolysis , endocrinology , risk factor , gastroenterology

Plasminogen activator inhibitor (PAI)-1, a key regulator of fibrinolysis, is associated with increased risk of coronary heart disease (CHD) and is a potential therapeutic target for CHD. However, the relationship between PAI-1 and the most common diabetic microvascular complication, retinopathy, is unclear. The purpose of this study was to assess the relationship between PAI-1 activity and both retinopathy and CHD in type 2 diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research